Sun Pharmaceutical’s record is a study in scale and strain: seven years of unqualified audit opinions sit beside a decade of recurring exceptional charges that have repeatedly reset the profit line, while a ₹13,420 crore related-party loan and unresolved U.S. regulatory actions at four plants keep the balance sheet and the manufacturing base under a cloud.
Key findings
- A ₹10,955 crore unsecured related-party loan matures in March 2026, and subsidiary loans are routinely renewed to settle fallen-dues
Major- The standalone entity carries an unsecured loan from a related party of ₹10,954.47 crore as at March 31, 2025, taken on March 31, 2021, repayable by March 31, 2026, at 7.5% p.a.. The auditor’s CARO report for FY2024-25 states that a loan of ₹1,000.00 crore to wholly owned subsidiaries was renewed to settle loans that had fallen due, representing 100% of total loans granted during the year. Credit impairment of receivables from wholly owned subsidiaries rose from ₹5.49 crore at March 31, 2024 to ₹113.94 crore at March 31, 2025. - Exceptional items recur annually, and a ₹13,420 crore related-party loan sits on the standalone balance sheet
Major- Exceptional items exceeded 5% of PBT in 6 of the last 10 years, with at least one exceptional item recorded in 9 of those 10 years. The standalone balance sheet carries an unsecured loan from a related party of ₹13,419.99 crore as at March 31, 2026, renewed on March 30, 2026, repayable by March 30, 2029, bearing interest at 7.5% p.a.. The NCLT approved a Composite Scheme of Arrangement on October 7, 2025, amalgamating five wholly-owned subsidiaries into the Company with an appointed date of April 1, 2023, and prior-period financial results were restated. - Recurring impairment charges on acquired intangibles and subsidiary investments span five years
Major- In FY2023, the standalone entity recorded an exceptional impairment charge of ₹2,937.79 crore on its investment in equity and preference shares of Sun Pharma Holdings, Mauritius. In FY2026, the company recorded an exceptional item of ₹287.64 crore for discontinuation of development work of SCD-044, including impairment of an acquired intangible asset under development of ₹151.49 crore. The discount rate used for the consolidated goodwill impairment test ranged from 2.8% to 14.3% for March 31, 2026. - The subsidiary empire spans hundreds of entities, with persistent consolidation gaps and deeply negative net worth in key units
Minor- Consolidated PAT was ₹11,565 crore versus standalone PAT of ₹2,623 crore in FY26, meaning 77% of group profit resided in subsidiaries. In FY24, three subsidiaries had negative net worth exceeding ₹5,000 crore each: Sun Pharma France ₹(5,524.6) crore, Ohm Laboratories ₹(31,478.4) crore, and Ranbaxy Inc. ₹(32,391.3) crore. - Revenue recognition is a recurring Key Audit Matter, and receivable days have risen to 97
Minor- The auditor identified rebates, discounts, chargebacks, returns and other allowances as a Key Audit Matter in each of the last four annual reports (FY22-FY25), citing significant judgement particularly for the US business. Consolidated trade receivables stood at ₹15,510 crore as of March 31, 2026, with receivable days rising to 97 days in FY26 from 91 days in FY25 and 85 days in FY24. - Operating cash flow covers profit comfortably but weakened sharply in FY23
Clean- Consolidated CFO/PAT was 1.07x in FY26, 1.28x in FY25, 1.26x in FY24, 0.58x in FY23, 2.64x in FY22, and 2.70x in FY21. Consolidated free cash flow was ₹8,906 crore in FY26 and ₹12,005 crore in FY25. The Board approved a buyback of up to ₹1,700 crore at a maximum price of ₹425 per share on 17 March 2020; no shares were bought back because the volume-weighted average market price exceeded the maximum buyback price.
What to watch
- Halol facility OAI and import alert. No scheduled re-inspection date as of the Q4 FY2026 transcript.
- Mohali facility OAI and Consent Decree Non-Compliance letter. No scheduled update as of the FY2025-26 Annual Report.
- Dadra facility Warning Letter and OAI status. Corrective measures ongoing as of the FY2025-26 Annual Report.
- Lipitor antitrust appeal. Pending before the U.S. Third Circuit; oral argument not yet scheduled as of the FY2024-25 Annual Report.
- Repayment of the ₹13,419.99 crore unsecured related-party loan. Due by March 30, 2029.
Bottom line: This is a disclosed and audited record with real cash conversion and a clean audit trail of opinions. The risk sits in three places: the unresolved U.S. FDA actions that keep four plants under a regulatory cloud, the recurring exceptional charges that have made the reported profit line a moving target for a decade, and the large related-party loans that tie up standalone capital. Watch the FDA re-inspection dates, the Lipitor appeal, and whether the ₹13,420 crore loan is repaid or renewed again.